Liquidia Corporation (LQDA) fair value analysis
Nasdaq · Updated 2026-09-07
Liquidia Corporation is a biopharmaceutical company that develops and commercializes medicines using its proprietary PRINT technology platform for targeted drug delivery. The company is based in Research Triangle Park, North Carolina and operates in the healthcare sector.
Valuation status
Awaiting full valuationLQDA does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $83.85
- Sector
- Healthcare
- 12-month range
- $22.05–$83.85
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- B-
- Leverage
- Moderate
- RSI zone
- Neutral
- 50/200-day trend
- Uptrend
- 52-week position
- The top quarter of its range
What our data shows for LQDA
- Shares are trading in the upper third of their 12-month price range of $22.05–$83.85.
- The 14-day relative strength index sits at a neutral 31.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LQDA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent LQDA news
TickrTrends' derived news-sentiment signal for LQDA is currently leaning positive, computed from recent coverage.
- Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations (finance.yahoo.com, 2026-09-03)
TickrTrends take: Liquidia Corporation operates in the Healthcare sector and is currently under TickrTrends review awaiting full valuation. The outperformance of Yutrepia's commercial launch relative to expectations may become a material factor in the valuation analysis once a complete assessment is conducted. Revenue trajectory and market adoption rates for this product will be key metrics for determining the company's fundamental value in the coming periods. - LQDA Looks 75.0% Undervalued on GF Value™ (gurufocus.com, 2026-09-03)
TickrTrends take: LQDA operates in the Healthcare sector where valuation metrics significantly influence investment thesis development. The company's current TickrTrends assessment remains awaiting full valuation, suggesting additional fundamental analysis is needed to establish a comprehensive valuation framework. A valuation-focused reader should monitor how LQDA's underlying financial metrics and sector dynamics evolve, as these factors will be instrumental in determining whether TickrTrends' full valuation assessment aligns with broader market pricing. - Liquidia: A Linear Launch Priced For Exponential Growth (NASDAQ:LQDA) (seekingalpha.com, 2026-08-28)
TickrTrends take: Liquidia operates in the Healthcare sector where companies often experience significant valuation shifts based on product launch trajectories and commercial execution. The headline's reference to pricing for exponential growth suggests market expectations that extend beyond the current linear launch phase, which aligns with TickrTrends' awaiting full valuation status as the company's true value proposition may not yet be fully reflected in market pricing. Investors monitoring LQDA's valuation should track whether actual growth rates and market adoption metrics match the growth assumptions currently embedded in the stock price.
What people are saying
Follow the LQDA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is LQDA stock undervalued?
LQDA does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is LQDA's TickrTrends verdict?
LQDA is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is LQDA overbought or oversold?
LQDA's 14-day RSI is in neutral territory - neither overbought nor oversold.